A Form 4 filed on August 17, 2026 discloses that Shiraz Shabanali Ladiwala, a director of Mesa Laboratories Inc /CO/, received 3,810 shares of common stock upon the vesting of restricted stock units on August 15, 2026.

Key Highlights

  • Reporting person: Shiraz Shabanali Ladiwala, identified as a Director of Mesa Laboratories Inc /CO/.
  • Transaction date: August 15, 2026, with the filing submitted August 17, 2026.
  • Shares acquired: 3,810 shares of common stock via transaction code M (conversion of derivative security), at a price of $0.
  • RSU conversion: 3,810 Restricted Stock Units vested on August 15, 2026; each RSU represented a contingent right to receive one share of common stock.
  • Post-transaction ownership: Ladiwala directly beneficially owns 12,333 shares of common stock following the transaction.
  • Remaining derivative securities: Zero RSUs remain beneficially owned following the reported transaction.

Mesa Laboratories Director Ladiwala Reports RSU Vest and Share Acquisition

According to the Form 4 filing, Shiraz Shabanali Ladiwala, a director at Mesa Laboratories Inc /CO/ (NASDAQ:MLAB), reported the vesting of 3,810 Restricted Stock Units on August 15, 2026. The filing states that each RSU represented "a contingent right to receive one share of the Issuer's common stock." The conversion is recorded under transaction code M and carried a price of $0, reflecting the nature of an RSU vest rather than an open-market purchase.

The Table II entry for the derivative security, labeled "Restricted Stock Units - 6," shows that 3,810 RSUs were disposed of via the same M-coded transaction, with zero derivative securities remaining following the event. The underlying security for the RSUs is listed as common stock, with an amount of 3,810 shares, and the expiration date field is noted as "Not Applicable" in the filing's explanation of responses.

Following the reported transaction, Ladiwala directly holds 12,333 shares of Mesa Laboratories common stock, according to Table I of the filing. The Form 4 was signed by John Sakys under Power of Attorney by Shiraz Ladiwala and submitted on August 17, 2026.

What Was Disclosed

The filing reports the August 15, 2026 vesting of 3,810 RSUs held by Mesa Laboratories director Shiraz Shabanali Ladiwala, resulting in the acquisition of 3,810 common shares at $0 and a post-transaction direct ownership position of 12,333 shares.